Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:03 2024-05-31 EDT			5-day change	1st Jan Change
11.51 ^USD	-4.48%		+1.23%	-5.96%

05-20	Pulse Biosciences Moves New Record Date for Rights Offering	MT
05-14	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

December 06, 2022 at 05:19 pm

On November 30, 2022, Sandra Gardiner, the Chief Financial Officer of Pulse Biosciences, Inc. gave notice that she was resigning from the company. The Company expects to promptly begin a search for Ms. Gardiner's successor.

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences Moves New Record Date for Rights Offering	05-20	MT
Pulse Biosciences Appoints Burke Barrett as President, CEO	05-14	MT
Pulse Biosciences, Inc Announces CEO Changes	05-14	CI
Pulse Biosciences, Inc Announces Executive Changes	05-14	CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	05-09	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Sector Update: Health Care Stocks Slide Late Afternoon	04-01	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	04-01	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Sector Update: Health Care Stocks Ease Late Afternoon	03-08	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	03-08	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	03-08	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	02-14	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	01-02	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	01-02	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	01-02	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	12-20	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	12-14	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	12-01	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	11-27	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	11-27	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	11-21	MT

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	-5.96%	638M
THERMO FISHER SCIENTIFIC	+7.01%	217B
DANAHER CORPORATION	+11.01%	190B
INTUITIVE SURGICAL, INC.	+19.20%	143B
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B
SIEMENS HEALTHINEERS AG	+1.48%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.6B

Other Advanced Medical Equipment & Technology